639468-72-7

Usage

Uses

Used in Organic Synthesis:
Phenyl(tetrahydro-2H-pyran-4-yl)methanone is used as an intermediate in organic synthesis for the development of various chemical compounds. Its unique structure allows it to be a versatile building block in the creation of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, phenyl(tetrahydro-2H-pyran-4-yl)methanone is used as a key component in the design and synthesis of potential drug candidates. Its structural features may contribute to the development of new pharmaceuticals with novel mechanisms of action.
Used in Pharmaceutical Research:
Phenyl(tetrahydro-2H-pyran-4-yl)methanone is employed in pharmaceutical research to explore its potential as a therapeutic agent. Further studies are needed to understand its biological effects and evaluate its safety and efficacy in treating specific medical conditions.

Upstream product

• 4295-99-2 tetrahydro-2H-pyran-4-carbonitrile 
• 101765-10-0 tetrahydro-4-(methoxymethylene)-2H-pyran 
• 110238-91-0 tetrahydropyran-4-carboxylic acid methyl ester 
• 591-51-5 phenyllithium 
• 98-88-4 benzoyl chloride 
• 263257-15-4 (tetrahydro-2H-pyran-4-yl)magnesium chloride 
• 156353-01-4 N-methoxy-N-methyltetrahydro-2H-pyran-4-carboxamide 
• 34270-90-1 2,2'-diiodoethyl ether 
• 98-83-9 isopropenylbenzene 
• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 
• 50675-18-8 3,4,5,6-tetrahydro-2H-pyran-4-carbaldehyde 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 40191-32-0 tetrahydro-2H-pyran-4-carbonylchloride 
• 2674-04-6 diphenyl cadmium 

Downstream Products

• 855887-00-2 4-phenyl-5-aza-spiro[2.4]hept-4-ene 
• 1361052-17-6 C₁₈H₁₃F₅O₂ 
• 1800345-36-1 (S)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol 
• 1800345-36-1 (R)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol 

Relevant academic research and scientific papers

TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF

The present applicationpresent application relates to a compound represented by Formula (III) or a pharmaceutically acceptable salt, solvent compound, active metabolite, crystal polymorph, ester, isomer, or prodrug thereof. The application further provides a pharmaceutical composition comprising the compound represented by Formula (III) and a use thereof for preparing a bromodomain inhibitor for preventing or treating various diseases, such as inflammation and cancer, related to the bromodomain.

Stereospecific Palladium-Catalyzed Acylation of Enantioenriched Alkylcarbastannatranes: A General Alternative to Asymmetric Enolate Reactions

We report the development of a Pd-catalyzed process for the cross coupling of unactivated primary, secondary, and tertiary alkylcarbastannatrane nucleophiles with acyl electrophiles. Reactions involving optically active alkylcarbastannatranes occur with exceptional stereofidelity and with net retention of absolute configuration. Because the stereochemistry of the resulting products is entirely reagent-controlled, this process may be viewed as a general, alternative approach to the preparation of products typically accessed via asymmetric enolate methodologies. Additionally, we report a new method for the preparation of optically active alkylcarbastannatranes, which should facilitate their future use in stereospecific reactions.

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Non-substrate based, small molecule inhibitors of the human isoprenylcysteine carboxyl methyltransferase

Activating mutations of human K-Ras proteins are among the most common oncogenic mutations, present in approximately 30% of all human cancers. Posttranslational modifications to K-Ras guide it to the plasma membrane and disruption of this localization inhibits the growth of Ras-driven cancers. The human isoprenylcysteine carboxyl methyltransferase (hIcmt) enzyme catalyzes the final α-carboxyl methylesterification of the C-terminal farnesyl cysteine of K-Ras, which is necessary for its proper localization. Thus, hIcmt inhibition is a regarded as a promising cancer therapy. A high quality inhibitor of hIcmt with in vivo activity would advance hIcmt research and drug development. Herein, Wwe report the results of a screen for small molecule hIcmt inhibitors in a library of molecules that were not hIcmt substrate analogs. The lead compound identified by this screen (1) was modified to remove chemical liabilities and to increase potency. The most potent resulting compound (5) inhibited hIcmt in vitro with low micromolar potency (IC50 = 1.5 ± 0.2 μM) and was kinetically characterized as a competitive inhibitor for prenylated substrates and a non-competitive inhibitor for the cofactor and methyl donor S-adenosylmethionine (SAM). These inhibitors offer important structure activity relationships for the future development of hIcmt inhibitors with in vivo activity.

NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS

The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS

The present invention is directed to tricyclic compounds (I), pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The present teaching provide indazole compounds represented by Structural Formulae (I) or (I') or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as T

One-pot arylative epoxidation of ketones by employing amphoteric bromoperfluoroarenes

A one-pot cascade synthesis of perfluoroaryl oxiranes 2 by the arylative epoxidation of enolizable ketones 1 with bromopentafluorobenzene (PFPBr) and derivatives (3) is reported. PFPBr is utilized as an equivalent of Br + and PFP- in

The "reverse-tethered" ruthenium (II) catalyst for asymmetric transfer hydrogenation: Further applications

The attachment of a tethering group from the basic nitrogen atom to the arene ligand of a ruthenium(II) catalyst greatly improves its ability to catalyze asymmetric transfer hydrogenation (ATH) reactions. In this paper, we describe further applications of this versatile system to an extended substrate range.

Syntheses and Binding Studies of New [(Aryl)(aryloxy)methyl]piperidine Derivatives and Related Compounds as Potential Antidepressant Drugs with High Affinity for Serotonin (5-HT) and Norepinephrine (NE) Transporters

In a wide search program toward new, efficient, and fast-acting antidepressant drugs, we have prepared series of new compounds having an (aryl)(aryloxy)methyl moiety linked directly or through a methylene chain to different substituted and unsubstituted cycles (isoquinoline, piperazine, piperidine, tetrahydropyran, or cyclopentane). These compounds have been evaluated for their affinities for serotonin (5-HT) transporter (SERT) and 5-HT1A and 5-HT2A receptors. Racemic mixtures of 4-[(aryl)(aryloxy)methyl]piperidine derivatives showed much higher affinity values for SERT than fluoxetine and resulted in lack of affinity for 5-HT 1A and 5-HT2A receptors. Some of these racemic mixtures were resolved to their enantiomers and tested for binding to norepinephrine (NE) transporter (NET), dopamine (DA) transporter (DAT), and α2 receptor. Several of these enantiomers [(-)-15b, (-)-15j, (-)-15t, (+)-15u] displayed a dual binding profile with affinities for SERT and NET with K i i = 1.9 and 13.5 nM, respectively), and further pharmacological characterization is in progress for its evaluation as a antidepressant.